Eleven-Year-Old MPN Hero Remains Positive in the Face of Uncertainty


Cannon McMullin was diagnosed with essential thrombocythemia at 8 years old and has remained positive through years of treatment by focusing on the things he likes to do.

Cannon McMullin was diagnosed with essential thrombocythemia (ET) at 8 years old, and now at age 11, has been living with the disease for 3 years. Cannon is the youngest of his siblings but has shown the poise of someone much older than him as he regularly travels for treatments and checkups with his parents, making him an MPN Hero and example for all patients to look too.

While Cannon has had his struggles with the disease the current treatment, he is on has allowed him to live a mostly normal life and continue to pursue the activities he loves, like basketball. Cannon is also a part of a clinical study investigating a new treatment, and Cannon knows that his participation in this trial is vital to the ongoing study of patients with ET, but more importantly, he’s doing it to help patients like him.

In an interview with CURE, Cannon discussed how he remains positive and some of the things he thinks about while undergoing treatment and traveling for meetings with physicians.


I just try to think of things that make me happy and just try not to think of the disease that I have. Like, I like sports games or like Call of Duty and fortnight, games like those.

In the summer we live really close to a lake, and so we'll put our kayaks down a little bit down the road then we'll kayak down to the beach and then drive back to our house.

Related Videos
Jessica McDade, B.S.N., RN, OCN, in an interview with CURE
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
A man with a dark gray button-up shirt with glasses and cropped brown hair.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE